文献速递肝病消化道肿瘤与早癌

NAFLD且肝酶正常患者的肝硬化与肝癌风险

Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
PubMed 文献 · Hepatology · 2020-01-01

该回顾性队列研究基于美国退伍军人健康管理局数据库,比较了脂肪肝伴正常ALT、脂肪肝伴升高ALT及无脂肪肝正常ALT三组患者的肝硬化和肝细胞癌发生率。结果显示脂肪肝伴正常ALT者的肝硬化和肝癌风险显著低于脂肪肝伴升高ALT者,且与无脂肪肝者无显著差异。

要点

  • 脂肪肝伴持续正常ALT者肝硬化风险显著低于脂肪肝伴ALT升高者。
  • 脂肪肝伴正常ALT者肝癌风险与无脂肪肝者无显著差异。
  • 脂肪肝伴ALT升高者肝硬化风险增高,但肝癌风险未达统计学显著。

核心结论

  • 肝脂肪变伴持续正常ALT者肝硬化风险低于肝脂肪变伴ALT升高者,且与无肝脂肪变临床队列无差异。

研究设计与样本

  • 回顾性队列研究,使用美国退伍军人健康管理局企业数据仓库,纳入3522例脂肪变/正常ALT、15419例脂肪变/升高ALT和9267例无脂肪变/正常ALT患者。

主要发现

  • 脂肪变/正常ALT组肝硬化和肝癌发生率分别为1.22(95%CI 0.83-1.74)和0.20(95%CI 0.06-0.46)/1000人年。
  • 脂肪变/升高ALT组肝硬化和肝癌发生率分别为3.85(95%CI 3.50-4.23)和0.37(95%CI 0.26-0.49)/1000人年。
  • 脂肪变/升高ALT组较脂肪变/正常ALT组肝硬化风险升高(调整HR 3.37,95%CI 2.34-4.86,P<0.01)。
  • 脂肪变/升高ALT组肝癌风险未达统计学显著(HR 2.07,95%CI 0.82-5.28,P=0.13)。

临床怎么用

  • 对于NAFLD且ALT持续正常的患者,肝硬化风险较低,可参考无脂肪肝人群进行管理。

局限性

  • 研究为回顾性队列,以男性退伍军人为主(>90%),外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The long-term risk of disease for patients with nonalcoholic fatty liver disease (NAFLD) in the absence of elevated enzymes is unclear. We conducted a retrospective cohort study using the Corporate Data Warehouse of the Veterans Health Administration. APPROACH AND RESULTS: We classified patients into three groups: patients with steatosis/normal alanine aminotransferase (ALT), steatosis/elevated ALT, and no steatosis/normal ALT. We examined incidence rates for cirrhosis and hepatocellular carcinoma (HCC) and conducted cause-specific hazard models to evaluate the risk of cirrhosis and HCC. We identified 3,522 patients with steatosis/normal ALT, 15,419 patients with steatosis/elevated ALT, and 9,267 patients with no steatosis/normal ALT. The mean age in each group was 58.9, 54.7 and 59.3 years, respectively; over 90% were men. Compared to patients with hepatic steatosis/normal ALT, those with steatosis/elevated ALT were younger and more likely to be obese (both P < 0.01). In patients with steatosis/normal ALT, the incidence rates of cirrhosis and HCC were 1.22 (95% confidence interval [CI]: 0.83-1.74) and 0.20 (95% CI: 0.06-0.46) per 1,000 person-years, respectively; this was lower than in patients with steatosis/elevated ALT (cirrhosis: 3.85; 95% CI: 3.50-4.23, and HCC: 0.37; 95% CI: 0.26-0.49). Patients with steatosis/elevated ALT had a higher risk of developing cirrhosis (adjusted hazard ratio: 3.37; 95% CI: 2.34-4.86; P < 0.01) than patients with steatosis/normal ALT; they also had a higher risk of HCC, although it did not reach statistical significance (hazard ratio: 2.07; 95% CI: 0.82-5.28; P = 0.13). The risk of cirrhosis and HCC in patients with steatosis/normal ALT and those without steatosis was not significantly different. CONCLUSIONS: Patients with hepatic steatosis with persistently normal ALT are at lower risk for cirrhosis compared to those with steatosis and elevated ALT and not different from the risk in a clinical cohort without hepatic steatosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Natarajan Y, Kramer JR, Yu X, et al. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020. PMID: 32022277. doi:10.1002/hep.31157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。